Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Enanta Pharmaceuticals Inc
CEO
Dr. Jay R. Luly
Employees
160
Industry
Biotechnology
Sector
Healthcare
Market cap
$245M
Company details
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Revenue
Revenue (Rev)
$79.20M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$6.36
Margin profit
-160.27%
52 week low
$8.17
52 week high
$17.459999
50-day simple moving average
$12.22
200-day simple moving average
$12.51
Percent held by insiders
6.09%
Percent held by institutions
104.52%
Dividend yield
0.00%
